Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic …
M Barkhordar, B Chahardouli, A Biglari… - Frontiers in …, 2023 - frontiersin.org
Background Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients must be
vaccinated against SARS-CoV-2 as quickly as possible after transplantation. The difficulty in …
vaccinated against SARS-CoV-2 as quickly as possible after transplantation. The difficulty in …
Antibodies to NCP, RBD and S2 SARS-CoV-2 in vaccinated and unvaccinated healthcare workers
A Błaszczuk, A Michalski, M Malm, B Drop… - Vaccines, 2022 - mdpi.com
In a few months, the SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. In
Poland, 6 million cases of the disease and 113,000 deaths from COVID-19 have been …
Poland, 6 million cases of the disease and 113,000 deaths from COVID-19 have been …
Evaluation of safety and immunogenicity of a recombinant receptor-binding domain (RBD)-tetanus toxoid (TT) conjugated SARS-CoV-2 vaccine (PastoCovac) in …
Background: The urgent need for prompt SARS-CoV-2 immunization of hematopoietic stem
cell transplant (HSCT) recipients in an endemic area raises many challenges regarding …
cell transplant (HSCT) recipients in an endemic area raises many challenges regarding …